skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis

Review

(1130) Views  (517) Full article downloads

Authors: Martha K Daddario, Jennifer K Hagerman, Michael E Klepser

Published Date October 2010 Volume 2010:3 Pages 123 - 132
DOI: http://dx.doi.org/10.2147/IDR.S7838

Martha K Daddario1, Jennifer K Hagerman2, Michael E Klepser2

1Spectrum Health, Grand Rapids, Michigan; 2Ferris State University College of Pharmacy, Kalamazoo, Michigan, USA

Abstract: Progressive obstructive lung disease is a characteristic component of cystic fibrosis (CF). It is the pulmonary manifestations, including obstruction and endobronchial infection, which directly contribute to the premature mortality of patients affected with CF. Due to the devastating effects on the pulmonary system, interest abounds in ways to improve antimicrobial delivery to the lungs and to impact clinical patient outcomes positively, whilst minimizing systemic toxicities. Recently, aztreonam lysine for inhalation solution, a new monobactam formulation, was approved by the US Food and Drug Administration for use in a subgroup of CF patients with Pseudomonas aeruginosa to improve respiratory symptoms. The purpose of this review is to present a summary of relevant pharmacologic, microbiologic, and clinical data related to the use of aztreonam lysine for inhalation in patients with CF.

Keywords: aztreonam, cystic fibrosis, inhaled, aerosolized, antibiotic, Pseudomonas aeruginosa








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Methicillin-resistant Staphylococcus aureus in HIV-infected patients
Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens
Multidrug and extensively drug-resistant tuberculosis from a general practice perspective
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents
Current strategies for the prevention and management of central line-associated bloodstream infections
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University